Journal article icon

Journal article

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Abstract:

BACKGROUND
The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.

METHODS
We performed three open-label, dose-escalation phase 1 trials and one randomized, double-blind, controlled phase 1 trial to assess the safety, side-effect profile, and immunogenicity of rVSV-ZEBOV at various doses in 158 healthy adul...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/NEJMoa1502924

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Tropical Medicine
Role:
Author
Wellcome Trust More from this funder
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
374
Issue:
17
Pages:
1647-1660
Publication date:
2016-04-28
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Source identifiers:
522529
Pubs id:
pubs:522529
UUID:
uuid:6b35ee09-7e09-4908-a98d-ded6a2f6cf7c
Local pid:
pubs:522529
Deposit date:
2016-05-25

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP